{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:37:03Z","timestamp":1788482223501,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004792","name":"Minist\u00e8re de l'Enseignement Sup\u00e9rieur et de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.phrs.2024.107438","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:28:54Z","timestamp":1727677734000},"page":"107438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Revisiting the nature and pharmacodynamics of tacrolimus metabolites"],"prefix":"10.1016","volume":"209","author":[{"given":"Rudy","family":"Mevizou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Aouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Ludovic","family":"Sauvage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Arnion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Pinault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gildas","family":"Bertho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolphe","family":"Alves de Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Lopez-Noriega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Di Meo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2024.107438_bib1","series-title":"The Search for Anti-Inflammatory Drugs: Case Histories from Concept to Clinic [Internet]","first-page":"27","article-title":"The history of the discovery and development of cyclosporine (Sandimmune\u00ae)","author":"Borel","year":"1995"},{"issue":"25","key":"10.1016\/j.phrs.2024.107438_bib2","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2024.107438_bib3","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0041-1345(96)00270-9","article-title":"FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study","volume":"29","author":"Miller","year":"1997","journal-title":"Transpl. Proc."},{"issue":"1 Pt 2","key":"10.1016\/j.phrs.2024.107438_bib4","first-page":"940","article-title":"Measurement of FK 506 by HPLC and isolation and characterization of its metabolites","volume":"23","author":"Christians","year":"1991","journal-title":"Transpl. Proc."},{"issue":"6","key":"10.1016\/j.phrs.2024.107438_bib5","first-page":"971","article-title":"Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone","volume":"21","author":"Iwasaki","year":"1993","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"issue":"1","key":"10.1016\/j.phrs.2024.107438_bib6","first-page":"28","article-title":"Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506","volume":"23","author":"Iwasaki","year":"1995","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"issue":"10","key":"10.1016\/j.phrs.2024.107438_bib7","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/clinchem\/38.10.2025","article-title":"Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients","volume":"38","author":"Christians","year":"1992","journal-title":"Clin. Chem."},{"issue":"9","key":"10.1016\/j.phrs.2024.107438_bib8","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/clinchem\/42.9.1426","article-title":"Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients","volume":"42","author":"Gonschior","year":"1996","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2024.107438_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0378-4347(00)00380-7","article-title":"Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants","volume":"748","author":"Christians","year":"2000","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"issue":"2","key":"10.1016\/j.phrs.2024.107438_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/FTD.0b013e31824b0bfb","article-title":"Quantification of tacrolimus and three demethylated metabolites in human whole blood using LC-ESI-MS\/MS","volume":"34","author":"Dubbelboer","year":"2012","journal-title":"Ther. Drug Monit."},{"issue":"5","key":"10.1016\/j.phrs.2024.107438_bib11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2133\/dmpk.23.313","article-title":"Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile","volume":"23","author":"Shimomura","year":"2008","journal-title":"Drug Metab. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2024.107438_bib12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1006\/bbrc.1994.1947","article-title":"Interaction of tacrolimus(FK506) and its metabolites with FKBP and calcineurin","volume":"202","author":"Tamura","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.phrs.2024.107438_bib13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1399-0012.2009.01181.x","article-title":"Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation","volume":"24","author":"Yanagimachi","year":"2010","journal-title":"Clin. Transpl."},{"issue":"5","key":"10.1016\/j.phrs.2024.107438_bib14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.transproceed.2015.12.133","article-title":"Tacrolimus metabolite M-III may have nephrotoxic and myelotoxic effects and increase the incidence of infections in kidney transplant recipients","volume":"48","author":"Zegarska","year":"2016","journal-title":"Transpl. Proc."},{"issue":"7","key":"10.1016\/j.phrs.2024.107438_bib15","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.transproceed.2018.03.025","article-title":"Evaluation of the relationship between concentrations of tacrolimus metabolites, 13-O-demethyl tacrolimus and 15-O-demethyl tacrolimus, and clinical and biochemical parameters in kidney transplant recipients","volume":"50","author":"Zegarska","year":"2018","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.phrs.2024.107438_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.16098","article-title":"Therapeutic drug monitoring of tacrolimus after kidney transplantation: trough concentration or area under curve-based monitoring?","author":"van Gelder","year":"2024","journal-title":"Br. J. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2024.107438_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1758-2946-4-17","article-title":"Avogadro: an advanced semantic chemical editor, visualization, and analysis platform","volume":"4","author":"Hanwell","year":"2012","journal-title":"J. Cheminf."},{"issue":"4","key":"10.1016\/j.phrs.2024.107438_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1107\/S0907444994014514","article-title":"Comparative X-ray structures of the major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and rapamycin","volume":"51","author":"Wilson","year":"1995","journal-title":"Acta Crystallogr D\u00a0Biol. Crystallogr"},{"issue":"1\u20133","key":"10.1016\/j.phrs.2024.107438_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00214-007-0310-x","volume":"120","author":"Zhao","year":"2008","journal-title":"Theor. Chem. Acc."},{"issue":"3","key":"10.1016\/j.phrs.2024.107438_bib20","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/cr.2016.14","article-title":"Cooperative autoinhibition and multi-level activation mechanisms of calcineurin","volume":"26","author":"Li","year":"2016","journal-title":"Cell Res."},{"issue":"3","key":"10.1016\/j.phrs.2024.107438_bib21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0092-8674(95)90439-5","article-title":"X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex","volume":"82","author":"Griffith","year":"1995","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.phrs.2024.107438_bib22","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/dmd.105.008680","article-title":"Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro","volume":"34","author":"Dai","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.phrs.2024.107438_bib23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2133\/dmpk.22.328","article-title":"Metabolism of Tacrolimus (FK506) and Recent Topics in Clinical Pharmacokinetics","volume":"22","author":"Iwasaki","year":"2007","journal-title":"Drug Metab. Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2024.107438_bib24","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1002\/hlca.19930760614","article-title":"Structural investigations of 13-O-demethyl-FK506 and its isomers generated by in vitro metabolism of FK506 using human-liver microsomes","volume":"76","author":"Sch\u00fcler","year":"1993","journal-title":"Helv. Chim. Acta"},{"issue":"10","key":"10.1016\/j.phrs.2024.107438_bib25","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1021\/ct400484u","article-title":"Absolute free energy of binding and entropy of the FKBP12-FK506 complex: effects of the force field","volume":"9","author":"General","year":"2013","journal-title":"J. Chem. Theory Comput."},{"issue":"9","key":"10.1016\/j.phrs.2024.107438_bib26","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1021\/acs.biochem.7b01256","article-title":"Conformational entropy of FK506 binding to FKBP12 determined by nuclear magnetic resonance relaxation and molecular dynamics simulations","volume":"57","author":"Solomentsev","year":"2018","journal-title":"Biochemistry"},{"issue":"12","key":"10.1016\/j.phrs.2024.107438_bib27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10822-019-00223-x","article-title":"Blinded prediction of protein\u2013ligand binding affinity using Amber thermodynamic integration for the 2018 D3R grand challenge 4","volume":"33","author":"Zou","year":"2019","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"23","key":"10.1016\/j.phrs.2024.107438_bib28","doi-asserted-by":"crossref","first-page":"9231","DOI":"10.1073\/pnas.87.23.9231","article-title":"Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin","volume":"87","author":"Bierer","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2024.107438_bib29","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1038\/s41467-019-12199-1","article-title":"Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents","volume":"10","author":"Juvvadi","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2024.107438_bib30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1006\/bbrc.1994.1947","article-title":"Interaction of tacrolimus(FK506) and its metabolites with FKBP and calcineurin","volume":"202","author":"Tamura","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824003839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824003839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T19:55:44Z","timestamp":1731009344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824003839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"alternative-id":["S1043661824003839"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107438","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting the nature and pharmacodynamics of tacrolimus metabolites","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107438"}}